Oppenheimer Holdings, Inc. set a $83.00 price target on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a research note released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms also recently weighed in on AGIO. SunTrust Banks, Inc. reaffirmed a buy rating and set a $80.00 price target on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed a buy rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Royal Bank Of Canada assumed coverage on shares of Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an outperform rating and a $78.00 price target on the stock. Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. Finally, Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals has an average rating of Buy and an average price target of $75.70.
Agios Pharmaceuticals (NASDAQ:AGIO) opened at $59.64 on Friday. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. Agios Pharmaceuticals’s revenue was up 26.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.63) earnings per share. equities analysts predict that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/11/20/oppenheimer-holdings-inc-reiterates-83-00-price-target-for-agios-pharmaceuticals-inc-agio.html.
In related news, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction on Friday, September 1st. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54. Following the sale, the insider now owns 8,410 shares of the company’s stock, valued at approximately $521,335.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 182,908 shares of company stock worth $12,391,239 in the last ninety days. 10.55% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the business. QS Investors LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $144,000. Cubist Systematic Strategies LLC grew its holdings in Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares in the last quarter. Aperio Group LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $206,000. Teacher Retirement System of Texas acquired a new position in Agios Pharmaceuticals during the 3rd quarter worth $225,000. Finally, S&CO Inc. acquired a new position in Agios Pharmaceuticals during the 3rd quarter worth $227,000. 92.64% of the stock is owned by institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.